← FDA DRUG APPROVALS

FDA ANDA · ANDA205245

METRONIDAZOLE

Sponsor: SOMERSET THERAPS LLC

APPLICATION
ANDA205245
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-23
LATEST ACTION
2024-10-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

METRONIDAZOLEPrescription
METRONIDAZOLE 250MG · TABLET · ORAL
METRONIDAZOLEPrescription
METRONIDAZOLE 500MG · TABLET · ORAL

Approval history

2024-10-25Labeling · Supplement 13 · standardAP
2024-07-08Labeling · Supplement 12 · standardAP
2024-06-18Labeling · Supplement 9 · standardAP
2024-06-18Labeling · Supplement 11 · standardAP
2021-08-18Labeling · Supplement 8 · standardAP
2019-07-29Labeling · Supplement 4 · standardAP
2015-09-23UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →